ImmuneWatch supports academics, clinical-stage biotech and pharma companies by using machine learning to identify T-cell receptor targets and analyze immune responses, helping improve (cancer) vaccines and immunotherapies. With strong roots in academia and an entrepreneurial mindset, the CEO Sander Wuyts bridges between scientific discovery and real-world application. His journey reflects how deep scientific expertise can evolve into impactful solutions that extend far beyond the lab.
